Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Shamash, J.
Right arrow Articles by Lister, T. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shamash, J.
Right arrow Articles by Lister, T. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 11:715-719, 2000
© 2000 European Society for Medical Oncology

research-article

Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: A two centre study

J. Shamash1,, S. M. Lee2, J. A. Radford2, A. Z. S. Rohatiner1, J. Chang2, G. R. Morgenstern2, J. H. Scarffe2, D. P. Deakin2 and T. A. Lister1

1ICRF Department of Medical Oncology, School of Medicine and Dentistry, St. Bartholomew's and Royal London Hospitals, Queen Mary and Westfield College Smithfield, London
2Department of Medical Oncology, Christie Hospital & Holt Radium Institute Manchester, UK

Correspondence to: J. Shamash, MD, Department of Medical Oncology, School of Medicine and Dentistry, St. Bartholomew's and Royal London Hospitals, Queen Mary and Westfield College, Smithfield, London El IBB, UK

Background: High-dose chemotherapy has an established role in recurrent or refractory Hodgkin's lymphoma (HL) although a significant proportion of patients subsequently relapse. This manuscript describes the clinical characteristics of such patients and documents their further management at two major UK cancer centres.

Patients and methods: Between 1987 and 1996 one hundred patients with recurrent or refractory HL received high-dose chemotherapy (HDCT) with autologous haematopoietic rescue. All had recurred within 12 months of initial therapy or had two or more recurrences.

Results: With a median follow-up of 2 years, 56 patients are currently progression-free. There were six treatment-related deaths. One patient died of pneumonia in remission. Thirty-seven patients have relapsed, intrapulmonary disease being seen for the first time in 53% and recurrence at previous sites of disease in 81%. Following recurrence, therapy was determined by circumstances: either one agent at a time was used (single sequential approach) or multiagent chemotherapy was chosen. There was a survival advantage for those who achieved a symptomatic response (13 vs. 4 months median, P = 0.0001). A trend towards longer survival was seen for those whose disease recurred beyond six months following high-dose chemotherapy and in those who received combination chemotherapy.

Conclusions: These results confirm that HDCT with autologous haematopoietic support is inadequate for about half the patients who receive it for high-risk HL. Relapse in the site of prior disease is the most likely pattern with intrapulmonary disease for the first time occurring frequently. It is possible to administer further chemotherapy after failure of HDCT, and both objective as well as subjective benefit can be achieved. A few patients appear to get long-term benefit from further treatment.

high dose, Hodgkin's lymphoma, patterns, relapse


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ASH Education BookHome page
M. Crump
Management of Hodgkin Lymphoma in Relapse after Autologous Stem Cell Transplant
Hematology, January 1, 2008; 2008(1): 326 - 333.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. L. Sorror, B. E. Storer, D. G. Maloney, B. M. Sandmaier, P. J. Martin, and R. Storb
Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia
Blood, January 1, 2008; 111(1): 446 - 452.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. A. Guadagnolo, R. S. Punglia, K. M. Kuntz, P. M. Mauch, and A. K. Ng
Cost-Effectiveness Analysis of Computerized Tomography in the Routine Follow-Up of Patients After Primary Treatment for Hodgkin's Disease
J. Clin. Oncol., September 1, 2006; 24(25): 4116 - 4122.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. O. Freytes, F. R. Loberiza, J. D. Rizzo, A. Bashey, C. N. Bredeson, M. S. Cairo, R. P. Gale, M. M. Horowitz, T. R. Klumpp, R. Martino, et al.
Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry
Blood, December 1, 2004; 104(12): 3797 - 3803.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Branson, R. Chopra, P. D. Kottaridis, G. McQuaker, A. Parker, S. Schey, R. K. Chakraverty, C. Craddock, D. W. Milligan, R. Pettengell, et al.
Role of Nonmyeloablative Allogeneic Stem-Cell Transplantation After Failure of Autologous Transplantation in Patients With Lymphoproliferative Malignancies
J. Clin. Oncol., October 1, 2002; 20(19): 4022 - 4031.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.